TCG Crossover is a science-driven investment firm dedicated to advancing disruptive medicines.
Employees: 11-50
Portfolio 24
| Date | Name | Website | Total Raised | Location |
| 01.01.2025 | Just a mom... | candidrx.com | - | - |
| 01.01.2025 | Adcendo | adcendo.com | $361.66M | Denmark, C... |
| 01.01.2025 | Beacon The... | beacontx.com | $170M | United Sta... |
| 01.01.2025 | ViceBio | vicebio.com | $100M | - |
| 12.06.2024 | Pheon Ther... | pheontx.com | $120M | United Kin... |
| 09.02.2024 | CG Oncolog... | cgoncology.com | $547M | United Sta... |
| 13.08.2023 | ADARx Phar... | adarx.com | $321M | Canada |
| 07.08.2023 | Gracell Bi... | gracellbio.com | $250M | China, Jia... |
| 25.07.2023 | Tourmaline... | tourmalinebio.com | $75M | United Sta... |
| 25.07.2023 | Versanis B... | versanisbio.com | $70M | United Sta... |
Show more
Persons 12
| Date | First Name | Last Name | Title | Location | |||
| - | Cariad | Chester | Managing P... | - | - | - | |
| - | Echo | Qin | - | - | - | - | |
| - | Chen | Yu | Managing P... | - | - | - | |
| - | George | Feng | Associate ... | - | - | - | |
| - | Giuliano | Marostica | Managing P... | - | - | - | |
| - | Julie | Yang | Principal | - | - | - | |
| - | Suan | Tuang | Associate | - | - | - | |
| - | Bill | Zhang | Analyst | - | - | - | |
| - | Brad | Balter | Head of Tr... | - | - | - | |
| - | James | Nguyen | Finance Ma... | - | - | - |
Show more
News 48
Show more
Mentions in press and media 4
| Date | Title | Description |
| 26.01.2026 | Corxel Raises Up to $287 Million In Series D1 To Advance Oral GLP 1 Program and Broader Cardiometabolic Pipeline | CORXEL Pharmaceuticals Limited said it has completed a Series D1 financing, raising up to $287 million to fund the development of CX11, its oral small molecule GLP-1 receptor agonist for obesity and overweight, as well as additional cardiom... |
| 14.10.2025 | Financial boost for publicly traded scale-ups | ADC Therapeutics SA, a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in ... |
| 05.01.2024 | TCG Crossover Closes $1B TCGX Fund II | TCG Crossover, a Palo Alto, CA- and NYC-based life sciences-focused investment firm with a flexible mandate to invest in both private and public companies, closed its second fund, TCGX Fund II, with $1B in capital. The fund received support... |
| 04.01.2024 | TCG Crossover (“TCGX”) Announces Oversubscribed $1B TCGX Fund II | - |